Welcome to LookChem.com Sign In|Join Free

CAS

  • or

3296-45-5

Post Buying Request

3296-45-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3296-45-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 3296-45-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,2,9 and 6 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 3296-45:
(6*3)+(5*2)+(4*9)+(3*6)+(2*4)+(1*5)=95
95 % 10 = 5
So 3296-45-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H12O3/c9-7-3-1-2-6(7)4-5-8(10)11/h6H,1-5H2,(H,10,11)

3296-45-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-(2-oxocyclopentyl)propanoic acid

1.2 Other means of identification

Product number -
Other names cyclopentanepropanoic acid,2-oxo

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3296-45-5 SDS

3296-45-5Relevant articles and documents

Acyl acid derivative and preparation method and medical application thereof

-

Paragraph 0419-0420; 0424-0426, (2020/07/02)

The invention relates to an acyl acid derivative as well as a preparation method and medical application thereof. Specifically, the invention relates to a compound represented by a general formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and the invention also relates to a use thereof as an active ingredient in the prevention and/or treatment of muscle atrophy-related diseases, including myogenic muscle atrophy, disuse muscle atrophy, senile muscle atrophy, neurogenic muscle atrophy, and a use in the prevention and/or treatment of obesity, fatty liver, cardiovascular and cerebrovascular diseases, metabolic diseases, and anti-aging, wherein the definition of each group in the general formula (I) is the same as the definition in the specification.

Asymmetric synthesis of tetracyclic benzo[a]quinolizidine targets

Allin, Steven M.,Gaskell, Sean N.,Elsegood, Mark R. J.,Martin, William P.

, p. 6448 - 6451 (2008/12/21)

(Chemical Equation Presented) We report a novel, facile, and asymmetric approach for the synthesis of polycyclic benzo[a]quinolizidine targets. In the formation of more functionalized derivatives, we have observed the generation of an iminium ether salt intermediate, formed during an unprecedented retro-Diels-Alder/N-acyliminium cyclization cascade. The iminium ether intermediate was isolated in good yield, characterized by X-ray crystallography, and subsequently applied as a synthetic building block.

CYANURES D'ACYLE ETHYLENIQUES V: ADDITION CONJUGUEE DES ETHERS D'ENOLS TRIMETHYLSILYLES.

El-Abed, Douniazad,Jellal, Abdelkebir,Santelli, Maurice

, p. 4503 - 4504 (2007/10/02)

Conjugate addition of silyl enol ethers to ethylenic acyl cyanides leads to δ-keto-acids or methyl esters after hydrolysis or methanolysis of reaction products.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 3296-45-5